Exousia Advanced Materials Acquire Surface Modification Intellectual Property

Exousia Advanced Materials, Inc. announces the acquisition of key intellectual property from Composite Particles, Inc. In an agreement with Composite Particles, Exousia acquired all the rights, title, interest and associated know-how in three patents pertaining to the surface modification of rubber and plastic particles. As a condition of the acquisition, the inventor, Dr. Bernard Bauman, will become an advisor to Exousia on technical extensions and improvements of the patents as well as matters related to new product development and commercialization.

The patents are significant as they provide Exousia with full ownership of the underlying intellectual property to its VISTAMER(R) rubber engineered particle, which Exousia previously sold under license. VISTAMER(R) rubber is a performance additive for plastics, concrete, epoxy, latex and polysulfides that improves impact resistance, tear resistance, adhesive strength, traction, toughness, flexibility and abrasion resistance. Exousia integrates surface- modified particles into its own products, such as E-CORE(TM) Structural Foam and its family of BIO-Shield(TM) industrial coatings, and sells them directly to manufacturers as a performance additive in their products. The patents will also allow Exousia to develop plastic-based particles, which significantly expands product development possibilities.

Surface-modified particles provide significant benefits for numerous industrial products. Exousia has developed high-volume applications where these particles can deliver breakthrough performance enhancements, and the Company is well positioned to successfully commercialize the technology. This acquisition represents a major milestone for the company.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.